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ABSTRACT 
Spaceflight-induced hypovolemia requires astronauts to mount a hyper-sympathetic response in 
order to complete a tilt test on landing day.  We tested the hypothesis that experimentally-
induced hypovolemia, in the absence of spaceflight, also requires a hyper-sympathetic response 
during tilt.  We studied 17 subjects during normovolemia and hypovolemia.  Plasma volume, tilt 
tolerance, supine and standing arterial pressure, heart rate and plasma norepinephrine (NE) levels 
were measured.  During hypovolemia tilts, subjects who increased their norepinephrine release 
above that during normovolemia tilts were significantly more likely to complete the test.  These 
results indicate that adequate norepinephrine release during tilt can overcome the hemodynamic 
compromises of hypovolemia.  This model may be used to identify susceptible astronauts prior 
to flight so that prospective, individualized countermeasures can be developed. 
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INTRODUCTION 
   The adaptations of humans to the conditions of spaceflight include profound 
physiological changes that can have deleterious effects upon landing.  It is difficult to predict 
these changes before flight because the unique physiological challenges of spaceflight often 
unmask symptoms that would not manifest in these healthy astronauts under normal conditions.  
A major physiological adaptation to spaceflight is a reduction in circulating blood volume [1-3], 
which has a significant effect on orthostatic tolerance.  Other systems must compensate for the 
volume loss if orthostatic tolerance is to be maintained after landing.  During postflight testing of 
orthostatic tolerance, only those who can mount an extra-ordinary sympathetic response are able 
to maintain upright blood pressures during stand or tilt tests.  A substantial percentage of 
astronauts cannot mount such a response and experience severe orthostatic hypotension and 
presyncope [1-4].  The ability to predict, before flight, those astronauts that will have orthostatic 
hypotension on landing day would be a major breakthrough in the effort to develop appropriate 
countermeasures.  To date, the only predictor of postflight orthostatic hypotension and 
presyncope in an individual astronaut has been the tilt test outcome from a prior flight [5].  
Preflight identification of susceptibility is difficult because, prior to flight, large sympathetic 
responses are not needed to maintain upright posture.  Thus incidents of presyncope preflight are 
very rare in these normal healthy astronauts.  We theorized that, since loss of blood volume is a 
large driver of postflight orthostatic hypotension, it may be possible to reproduce the landing day 
presyncope by reproducing the landing day hypovolemia.  In a ground-based study, we used a 
regimen of an intravenous dose of furosemide plus a low salt diet to induce hypovolemia.  We 
tested the hypothesis that the incidence of presyncope during upright tilt testing would be the 
same during hypovolemia as it is on landing day, and that the underlying cause of presyncope 
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would be inadequate compensatory sympathetic responses.  If true, we would be able to predict 
before flight which individuals would become presyncopal after spaceflight, so that 
countermeasures could be prescribed prospectively for them.   
METHODS  
This study was approved by the Johnson Space Center Committee for the Protection of 
Human Subjects.  All subjects signed informed consent documents.  Subjects were 12 men and 5 
women, aged 40.9 + 2 years.  Six of these were astronauts (five men and one woman), for whom 
we were able to compare their previous preflight and postflight tilt test outcomes with their 
current normovolemia and hypovolemia tilt test outcomes.  Subjects came to the laboratory on 
three occasions, with tilt tests occurring on days 1 and 3.  On day 1 (normovolemia day), subjects 
had consumed a minimum of 2 grams of NaCl every day for a week.  On day 2, subjects had 
voluntarily reduced their salt intake for the prior three days and initial hypovolemia was achieved 
by the slow infusion of 0.5 mg/kg of furosemide at a rate of 4 mg/min.  This was followed by 36 
hours of a very low sodium diet (10mEq/day).  We chose this regimen to avoid the acute 
vasoactive effects of furosemide and to achieve a steady state hypovolemia [6].  Day 3 
(hypovolemia day) began 40 hours after the furosemide infusion.  Days 1 and 3 were separated 
by at least two weeks, and for female subjects were always performed during menses.   
On each study day, subjects had abstained from taking any medications for the previous 
24 hours, had not eaten a heavy meal within 4 hours, had consumed a light snack within 2 hours, 
and had not exercised maximally within 24 hours.  Subjects were placed supine on a tilt table and 
instrumented for ECG, brachial artery pressure (Dinamap) and beat-to-beat finger arterial 
pressure (Finapres). An intravenous catheter was placed in an antecubital vein for blood draws.  
The subject then rested on the table for 20 minutes, at which time plasma volume was measured 
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using a carbon monoxide rebreathing technique [7,8].  A blood sample was drawn for plasma 
norepinephrine levels.  Measurements of heart rate and arterial pressure were obtained for 5 
minutes, after which the tilt table was inclined to 80o upright.  Measurements continued for 15 
minutes and a final blood sample was drawn.  If presyncopal symptoms caused early termination 
of the tilt test, the table was returned to the supine position while blood was drawn immediately.  
Catecholamines were later measured by radioenzymatic assay [9].   
Statistics 
All results are presented as means + SE.  The effect of hypovolemia on plasma volume, 
blood pressure, heart rate and delta norepinephrine (upright minus supine) was tested using 
repeated measures analyses of variance.  The dependent measures used in these analyses were 
first tested for normality and equal variance using the Kolmogorov-Smirnov test and the Levene 
Median test.  A Cox proportional hazards regression, with jackknifed standard errors to account 
for the small sample size and repeated measures, was used to determine which factors were most 
important in determining tilt survival time [10].  Estimates of the regression coefficients and the 
baseline hazard function were then used to generate tilt-time survival curves for various 
combinations of change in plasma volume and delta norepinephrine. 
RESULTS 
Plasma Volumes    
 Plasma volume indexes (PVI, plasma volume / body surface area), is shown for all 
subjects in Figure 1 for both the normovolemia and hypovolemia days.    Plasma volume index 
was significantly decreased on the hypovolemia day (P < 0.0001). The loss ranged from -0.02 to 
-0.59 L/m2.   
[Figure 1 here] 
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Supine Arterial Pressure and Heart Rate 
 There were no differences in arterial pressure between the normovolemia and 
hypovolemia days, but heart rate was higher during hypovolemia.  Baseline systolic and diastolic 
pressures were 114 + 3 mmHg and 66 + 2 mmHg during normovolemia and 114 + 3 mmHg and 
69 + 2  mmHg during hypovolemia (p = NS).  Baseline heart rate was 56 + 2 bpm during 
normovolemia and 63 + 3 bpm during hypovolemia (P < 0.0005).   
Orthostatic Tolerance 
Of the six astronaut subjects who participated in this study, the four who became 
presyncopal during tilt tests on landing day also became presyncopal during tilt tests on the 
hypovolemia day.  The two astronauts who did not become presyncopal on landing day did not 
become presyncopal during tests with hypovolemia.  Unfortunately, no preflight or postflight 
plasma volume or norepinephrine data were available so comparisons were not possible.   
Figure 2 presents original tracings during normovolemia and hypovolemia for one non-
presyncopal subject (top two panels) and one presyncopal subject (bottom two panels).  The 
presyncopal subject maintained upright tilt for only five minutes on the hypovolemia day.   
[Figure 2 here] 
Norepinephrine Responses 
[Figure 3 here] 
 
Figure 3 presents supine and standing plasma norepinephrine levels for the same two subjects are 
presented in Figure 2.  During normovolemia the two subjects had similar increases in 
norepinephrine levels during upright tilt.  During hypovolemia, they had similar supine plasma 
norepinephrine levels, but the presyncopal subject had no additional increase in response to tilt, 
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while the non-presyncopal subject had a greater than two-fold increase.  This same trend holds 
true for the entire group of subjects (figure 4).  
[Figure 4 here] 
 
Combined Responses 
The survival curves in Figure 5 show that the probability of surviving a 15 minute tilt test 
decreases with increasing plasma volume loss and increases with the increasing norepinephrine 
release.  Plasma volume losses of 0.2, 0.4 and 0.6 L/m2, and plasma NE increase of 0 (panel A), 
250 (panel B), 500 (panel C) and 750 pg/ml (panel D) were chosen for illustration.  The 
summary of Figure 5 is that adequate sympathetic compensation can protect tilt survival even in 
the face of profound hypovolemia.  
[Figure 5 here] 
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DISCUSSION 
This study describes a very important finding; that if astronauts and normal subjects are 
subjected to experimentally-induced hypovolemia that reproduces spaceflight-induced 
hypovolemia, they will self-separate into two groups, those who do and those who do not 
become presyncopal during an upright tilt test.  In the astronauts whom we tested under both 
conditions, the hypovolemia reproduced the occurrence of post-spaceflight presyncope with 
100% fidelity.  Moreover, the mechanism of presyncope in both conditions appears to be the 
same; the failure to mount the hyper-sympathetic response needed to overcome the 
hemodynamic compromise caused by hypovolemia.  Using this model, we showed that even 
with a plasma volume loss of 30%, subjects who can release enough norepinephrine still have an 
80% probability of completing 15 minutes of upright tilt. 
This model can provide new opportunities for the study of mechanisms of blood pressure 
control.  By driving subjects into a compromised hemodynamic state, we can measure the limits 
of sympathetic responsiveness.  The model offers the means to determine which astronauts may 
be susceptible to postflight orthostatic hypotension prior to their first flight, so that 
countermeasure treatments can be individualized and prescribed prospectively.  Within patient 
populations the model could be useful in the study of the interaction of volemic state and the 
sympathetic nervous system in both hypotension and hypertension. 
Spaceflight Relevance 
Our group has published several reports regarding post-spaceflight orthostatic 
hypotension that include data from over 100 astronaut subjects.  In each study we found subtle 
preflight differences between the responses of astronauts who were and were not destined to 
become presyncopal during tilt tests on landing day [1-4].  However, the differences were not 
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great enough to allow us to predict postflight presyncope.  The current study is a breakthrough in 
this effort.  
Many attempts have been made by this laboratory and others to restore plasma volume 
losses in astronauts prior to their return to Earth [11,12].  To date those attempts have been 
unsuccessful.  All of the astronauts who have been subjects in our flight studies had consumed 
the required fluid load of salt tablets and water (or its equivalent) prior to landing.  Still they 
average a 9% loss of plasma volume after both short [2,4], and long-duration flights [13].  It is 
clear that this is the major underlying factor for orthostatic hypotension.  In fact, we have shown 
that restoration of plasma volume in bedrest eliminates post-bedrest orthostatic intolerance [11].  
The key to postflight orthostatic tolerance is actually the degree to which the sympathetic 
nervous system can compensate for the volume loss [2,4,14].  Therefore, our more recent 
countermeasure development efforts have focused on α-adrenergic agonists to supplement 
sympathetic responses.  The α-agonist midodrine has been successful in preventing postflight 
orthostatic hypotension [15], but it may not be appropriate for all crew members.  The new 
hypovolemia model may be used as a quick screening test to compare relative efficacy of  new 
countermeasures, so that more choices will be available to crews.  The model could also be 
effective in identification of susceptible crew members and could eventually be used as a 
selection criterion for flight assignments. 
This model already has allowed us to compare the effects of hypovolemia alone with the 
effects of spaceflight on left ventricular mass, an area of some controversy.  It had been 
suggested by some that decreases in left ventricular mass after spaceflight might indicate cardiac 
atrophy associated with spaceflight and bedrest [16-18].  However, our hypovolemia model 
effected the same decrease in left ventricular mass as that seen on landing day [19].  This 
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suggests that the postflight reductions in mass may be secondary to simple physiologic fluid 
redistribution.  Other cardiovascular changes after spaceflight, such as decreased aerobic 
capacity, must also have a large hypovolemic component.  The same hypovolemia model could 
be used to separate the hypovolemia effect from the “deconditioning” effect.  
It is important to note that this model may “under-predict” susceptibility after longer 
duration missions, which last months rather than days.  We have shown that even crew members 
who were not presyncopal during tilt tests after short Shuttle flights become presyncopal after 
long flights [13].  It is thought that a central remodeling occurs as flight progresses due to lack of 
afferent baroreceptor input, such that efferent sympathetic responses may be blunted [3].  The 
usefulness of this hypovolemia model for longer flights will be mostly in preflight comparisons 
of the efficacy of various countermeasures or combinations of countermeasures.  
Summary 
 We report a new model which uses hypovolemia to force humans into a hemodynamic 
state that is similar to that after spaceflight.  This model can be used to test candidate 
countermeasures for postflight orthostatic hypotension and to identify crewmembers who will be 
most susceptible to that symptom on landing day.    
Limitations 
 Data published by this laboratory show that female astronauts are more susceptible to 
orthostatic hypotension after spaceflight [4], however, the results from this study do not clearly 
show gender differences during hypovolemia.  This may be explained by the different 
mechanisms of plasma volume reduction.  The female astronauts have plasma volume losses 
after flight that are three times greater than those of their male crewmates, probably due to their 
different center of gravity [20].  This contributed importantly to their susceptibility.  In the 
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current study, the hypovolemia was induced pharmacologically and there were no differences in 
plasma volume losses between men and women.  This is an important consideration in studies of 
this type.   
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Figure Captions 
Figure 1.  Plasma volume index (plasma volume normalized by body surface area) is 
shown for all subjects on the normovolemia (left) and hypovolemia (right) days. 
Figure 2.  Original tracings of arterial pressure and heart rate from tilt tests during 
normovolemia and hypovolemia in one non-presyncopal subject (top) and one presyncopal 
subject (bottom).  Note that the presyncopal subject remained upright for the entire test on the 
normovolemia day, but only withstood five minutes upright on the hypovolemia day.  The heavy 
arrows begin at the time of tilt. 
Figure 3.  Norepinephrine responses to tilt during normovolemia and hypovolemia in 
non-presyncopal and presyncopal subjects (right).  Previously published preflight and postflight 
norepinephrine responses to tilt have been re-plotted and are presented for comparison on the left 
(11).  Note the similarity between the change from preflight to postflight with that from 
normovolemia to hypovolemia. 
Figure 4.  Tilt-induced increase in norepinephrine for presyncopal (black) and non-
presyncopal (white) subjects during normovolemia (left) and hypovolemia (right). 
Figure 5.  Cox proportional hazard analysis prediction of tilt survival based on level of 
hypovolemia (PVI Loss: [             ]thick blue = 0.2 L/m2; [         ]thin red = 0.4 L/m2;  
[         ]dashed green = 0.6 L/m2) and sympathetic responsiveness (tilt-induced norepinephrine 
release: A = 0.0 pg/ml; B = 250 pg/ml; C = 500 pg/ml; D = 750 pg/ml) 
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